Dihydroberberine

Research Papers and Clinical Trials

Current research on dihydroberberine is emerging across multiple therapeutic areas, though the evidence base remains limited with mostly preclinical studies and few completed human trials.

Key Research Areas

Metabolic Disorders and Diabetes
Several recent studies focus on dihydroberberine's metabolic effects. One study published in Diabetes, Obesity & Metabolism (2026) investigated how dihydroberberine normalizes insulin secretion by regulating glucokinase, though specific study design details are not available from the current evidence. A comprehensive review in Food and Chemical Toxicology (2026) examined dihydroberberine's role in metabolic disorders, covering bioavailability, molecular mechanisms, and toxicology considerations.

Cancer Research
Research published in Phytomedicine (2026) explored dihydroberberine's effects in colorectal cancer, specifically examining how it regulates the ferroptosis-autophagy positive feedback loop by targeting PANX2. However, study methodology and sample sizes are not detailed in the available evidence.

Liver Disease
A study in Clinical and Molecular Hepatology (2026) investigated gut microbiota-mediated berberine metabolism in cholestatic liver disease, finding that it may ameliorate the condition by suppressing 5-hydroxytryptamine production.

Other Applications
Additional research has examined dihydroberberine's potential in inflammatory conditions, including its effects as a prostaglandin D synthase inhibitor for Duchenne muscular dystrophy and inflammation-related diseases, as well as applications in metabolic-associated steatotic liver disease (MASLD).

Clinical Trials

Completed Studies
Three clinical trials have been completed examining dihydroberberine:

• A bioavailability study comparing berberine and dihydroberberine and their glycemic impacts (NCT05021341)
• A trial examining metabolic differences between dihydroberberine and micellar berberine (NCT06202157)
• A study on green coffee extract's effects on blood glucose (NCT06137066), though its direct relevance to dihydroberberine is unclear

Ongoing and Future Research
One study examining dihydroberberine's effects on body composition and metabolic health in healthy adults is not yet recruiting participants (NCT07322679). One anti-inflammatory supplementation trial in chronic opiate patients was terminated (NCT05896878).

Research Limitations
The available evidence lacks detailed information about study methodologies, sample sizes, and specific findings from most studies. While research spans multiple therapeutic areas, the clinical evidence base remains thin, with most trials either completed without published results or still in planning phases.

Note: This synthesis is based on limited available evidence. Consult healthcare providers for medical advice regarding dihydroberberine use.